ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy
· seekingalpha.com
ARS Pharma has experienced a >65% decline since my previous 'Hold' rating, reflecting significant commercialization challenges. Click for more on SPRY stock.
This is my second ARS Pharmaceuticals ( SPRY ) article, following 07/2025's "ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine." In No...